Who makes GL0034 Dose Level 3?

GL0034 Dose Level 3 is developed by Sun Pharmaceutical Industries Limited.

What development phase is GL0034 Dose Level 3 in?

GL0034 Dose Level 3 is in Phase 2.

Last reviewed 2026-04-19 · How we verify

GL0034 Dose Level 3

Sun Pharmaceutical Industries Limited · Phase 2 active Small molecule

At a glance

Generic name	GL0034 Dose Level 3
Sponsor	Sun Pharmaceutical Industries Limited
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Efficacy and Safety of GL0034 in Overweight or Obese Adults With Type II Diabetes Mellitus (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

GL0034 Dose Level 3 CI brief — competitive landscape report
GL0034 Dose Level 3 updates RSS · CI watch RSS
Sun Pharmaceutical Industries Limited portfolio CI